Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

PROPOSED ADOPTION OF H SHARE AWARD SCHEME PROPOSED AUTHORIZATION TO THE BOARD AND/OR AUTHORIZED PERSON TO HANDLE MATTERS RELATING TO THE H SHARE AWARD SCHEME

PROPOSED ADOPTION OF H SHARE AWARD SCHEME

The board (the "**Board**") of directors (the "**Director(s)**") of CF PharmTech, Inc. (the "**Company**") announces that on November 12, 2025, it resolved to propose the adoption of the 2025 H Share Award Trust Scheme of the Company (the "**H Share Award Scheme**").

The H Share Award Scheme aims to attract, retain, and motivate key talent by aligning the interests of employees, management, and shareholders (the "**Shareholders**") of the Company, rewarding their contributions and driving the Company's sustained development and long-term success.

The H Share Award Scheme constitutes a scheme involving the existing shares of the Company as referenced under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), and shall be subject to the applicable disclosure requirements under Rule 17.12 of the Listing Rules. The H Share Award Scheme does not, however, involve the issue of new shares or the grant of options over any new securities of the Company under Chapter 17 of the Listing Rules. Therefore, its adoption does not require the approval of the Shareholders under the Listing Rules. Nevertheless, pursuant to the articles of association of the Company, the H Share Award Scheme and the related matters are subject to, among others, the approval of the Shareholders at the general meeting of the Company.

PROPOSED AUTHORIZATION TO THE BOARD AND/OR AUTHORIZED PERSON TO HANDLE MATTERS RELATING TO THE H SHARE AWARD SCHEME

To ensure the effective implementation of the H Share Award Scheme, the Board will seek Shareholder approval at the general meeting to authorize the Board and/or authorized person to administer all matters relating to the H Share Award Scheme at their sole discretion. The details of such authorization will be set out in the circular to be despatched to Shareholders thereafter.

The proposed adoption of the H Share Award Scheme and the proposed authorization are subject to Shareholders approval at the general meeting.

A circular containing, among others, the details and key terms of the H Share Award Scheme and the authorization details will be despatched to the Shareholders in due course.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, November 13, 2025

As at the date of this announcement, the Board comprises of Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.